Schedule 13D ownership disclosure
EDESA BIOTECH INC
Common Shares, without par value · CUSIP: 27966L306
Event date: 2025-02-12
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Velan Capital Master Fund LPReported CIK 0001964356
Shares: 427,926.00 · Class: 6.2%
- Velan Horizon Fund LP
Shares: 15,625.00 · Class: 0.2%
- Velan Capital Opportunity Fund II LLC
Shares: 250,000.00 · Class: 3.6%
- Velan Horizon GP LLC
Shares: 15,625.00 · Class: 0.2%
- Velan Capital Holdings LLCReported CIK 0001964353
Shares: 677,926.00 · Class: 9.8%
- Velan Capital Investment Management LPReported CIK 0001848809
Shares: 693,551.00 · Class: 9.99%
- Velan Capital Management LLCReported CIK 0001964355
Shares: 693,551.00 · Class: 9.99%
- Morgan AdamReported CIK 0001964335
Shares: 693,551.00 · Class: 9.99%
- VENKATARAMAN BALAJIReported CIK 0001114916
Shares: 693,551.00 · Class: 9.99%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000921895-25-000528
- Form type
- SCHEDULE 13D
- Filer
- Edesa Biotech, Inc.
- CIK
- CIK 1540159
- Filed
- Feb 18, 2025
- Reporting period
- Feb 12, 2025
- Description
- Schedule 13D beneficial ownership